Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of LY02404/Xuezhikang tablets in primary hyperlipidemia
ChiCTR2000033914Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jun 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Xuezhikang in familial hyperlipidemia (4 arms), sponsored by Peking University First Hospital. Primary endpoint: Low-density lipoprotein cholesterol. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
Xuezhikang
03
Conditions
familial hyperlipidemia
Beyond the preview
Go deeper on ChiCTR2000033914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033914.